Kiromic Biopharma Inc. (KRBP)

Overview

Kiromic BioPharma, Inc. is a pioneering entity in the clinical stage biotherapeutics domain, leveraging cutting-edge Gamma Delta T cell (GDT) technologies to bring forth therapeutic solutions for patients battling solid tumors. With its inception in 2006 and stationing in Houston, Texas, the company marked its evolution from Kiromic, Inc. to Kiromic BioPharma, Inc. in December 2019. Through its earnest commitment to innovation in oncology treatment, Kiromic BioPharma enters into strategic partnerships, exemplified by its license agreement with Longwood University and a research and development collaboration with Molipharma, S.R.L., to enhance its technological and developmental prowess.

Products and Services

• Deltacel-01
  

  Positioned as a frontrunner in the company’s clinical trial endeavors, Deltacel-01 is currently being investigated in a Phase 1 clinical trial targeting patients with non-small cell lung cancer. This innovative therapy underlines Kiromic BioPharma’s dedication to combating one of the most prevalent and challenging forms of cancer.

• Isocel
  

  Isocel represents a strategic combination therapy involving low-dose radiation, specifically formulated to address Mesothelin Isoform 2 positive solid malignancies. This approach reflects the company's precision in targeting specific cancer markers, thereby refining treatment efficacy.

• ALEXIS-ISO-1
  

  As an allogeneic GDT therapy product, ALEXIS-ISO-1 targets an isoform of mesothelin, highlighting the company’s commitment to developing off-the-shelf therapies that could potentially offer a broader applicability in cancer treatment, especially for solid tumors expressing specific biomarkers.

• Procel
  

  Procel is another combinatory therapy entailing low-dose radiation, this time focusing on PD-L1 positive solid malignancies. By targeting PD-L1, Procel is at the forefront of Kiromic BioPharma's endeavors to provide solutions for cancers utilizing a mechanism that inhibits the cancer cells' ability to evade the immune system.

• ALEXIS-PRO-1
  

  This allogeneic GDT therapy product, ALEXIS-PRO-1, aims at PD-L1, a pivotal marker in many solid malignancies. The targeting of PD-L1 signifies Kiromic BioPharma’s advanced therapeutic strategy in improving the immune system’s response against cancer cells, thus broadening the scope for effective treatments.